Ciclosporin
Brand names: Neoral, Sandimmun, Capimune, Deximune, Vanquoral
Ciclosporin is a calcineurin-inhibitor immunosuppressant used in rheumatology as a disease-modifying agent for severe rheumatoid arthritis and other autoimmune conditions unresponsive to first-line therapy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds cyclophilin and inhibits calcineurin, blocking the transcription of interleukin-2 and other cytokines and thereby suppressing T-lymphocyte activation.
Prescribing in practice
- Nephrotoxic and hypertensive — renal function and blood pressure must be measured before and regularly during treatment, with dose reduction or withdrawal if creatinine rises persistently.
- Numerous interactions occur via CYP3A4 and P-glycoprotein; avoid concurrent live vaccines and minimise other nephrotoxins.
- Prescribe and dispense by brand name because formulations are not interchangeable, and check the SPC for the relevant indication.
Monitoring
Monitor serum creatinine, blood pressure, potassium, liver function, lipids and (where indicated) blood ciclosporin concentrations during therapy.
Counselling the patient
- Report swelling, reduced urine output or persistent headache.
- Avoid grapefruit juice and tell clinicians about all other medicines.
- Use sun protection and attend monitoring appointments.
Evidence & guidelines
Long-standing use is supported by controlled trials and UK guidance for severe refractory inflammatory arthritis.
Reference: NICE TA180; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022